nach oben

Diabetologia

Erschienen in:

01.03.2016 | Mini-review

Treatment of gastrointestinal autonomic neuropathy

verfasst von: Hans Törnblom

Erschienen in: Diabetologia | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

The symptoms caused by gastrointestinal autonomic neuropathy in diabetes mellitus is important to highlight since it affects a large proportion of people with diabetes, regardless of whether this is type 1 or type 2. Gastroparesis and general signs of bowel dysfunction, such as constipation, diarrhoea and abdominal pain are most often encountered and involve both pharmacological and non-pharmacological treatment options. This mini-review summarises a presentation given at the ‘Diagnosis and treatment of autonomic diabetic neuropathy in the gut’ symposium at the 2015 annual meeting of the EASD. It is accompanied by another mini-review on a topic from this symposium (by Azpiroz and Malagelada, DOI: 10.1007/s00125-015-3831-1) and a commentary by the Session Chair, Péter Kempler (DOI: 10.1007/s00125-015-3826-y).

Lovell RM, Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10:712–721.e4CrossRefPubMed

Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M (2001) Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 161:1989–1996CrossRefPubMed

Pasricha PJ, Colvin R, Yates K et al (2011) Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 9:567–576.e1-4PubMedCentralCrossRefPubMed

Abrahamsson H (2007) Treatment options for patients with severe gastroparesis. Gut 56:877–883PubMedCentralCrossRefPubMed

Parkman HP, Yates KP, Hasler WL et al (2011) Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 141:486–498, 498.e1-7CrossRefPubMed

Olausson EA, Storsrud S, Grundin H, Isaksson M, Attvall S, Simren M (2014) A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol 109:375–385CrossRefPubMed

Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association (2004) American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 127:1592–1622CrossRefPubMed

Janssen P, Harris MS, Jones M et al (2013) The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol 108:1382–1391CrossRefPubMed

Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A (1982) Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med 96:444–446CrossRefPubMed

10.

McCallum RW, Ricci DA, Rakatansky H et al (1983) A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 6:463–467CrossRefPubMed

11.

Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW (1985) Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 7:25–32CrossRefPubMed

12.

Perkel MS, Moore C, Hersh T, Davidson ED (1979) Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci 24:662–666CrossRefPubMed

13.

Patterson D, Abell T, Rothstein R, Koch K, Barnett J (1999) A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 94:1230–1234PubMed

14.

Janssens J, Peeters TL, Vantrappen G et al (1990) Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 322:1028–1031CrossRefPubMed

15.

Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S (1993) Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 16:1511–1514CrossRefPubMed

16.

Tack J, Vanormelingen C (2014) Management of gastroparesis: beyond basics. Curr Treat Options Gastroenterol 12:468–477CrossRefPubMed

17.

Abell T, McCallum R, Hocking M et al (2003) Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 125:421–428CrossRefPubMed

18.

Abell TL, Van Cutsem E, Abrahamsson H et al (2002) Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 66:204–212CrossRefPubMed

19.

McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T (2010) Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 8:947–954CrossRefPubMed

20.

McCallum RW, Lin Z, Forster J, Roeser K, Hou Q, Sarosiek I (2011) Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol 9:314–319.e1CrossRefPubMed

21.

Ford AC, Suares NC (2011) Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 60:209–218CrossRefPubMed

22.

Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58:357–365CrossRefPubMed

23.

Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358:2344–2354CrossRefPubMed

24.

Quigley EM, Vandeplassche L, Kerstens R, Ausma J (2009) Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29:315–328CrossRefPubMed

25.

Tack J, Stanghellini V, Dubois D, Joseph A, Vandeplassche L, Kerstens R (2014) Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 26:21–27CrossRefPubMed

26.

Yiannakou Y, Piessevaux H, Bouchoucha M et al (2015) A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol 110:741–748PubMedCentralCrossRefPubMed

27.

Lembo AJ, Kurtz CB, Macdougall JE et al (2010) Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138:886–895.e1CrossRefPubMed

28.

Chey WD, Lembo AJ, Lavins BJ et al (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107:1702–1712CrossRefPubMed

29.

Lacy BE, Schey R, Shiff SJ et al (2015) Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial. PLoS One 10:e0134349PubMedCentralCrossRefPubMed

30.

Bharucha AE, Low P, Camilleri M et al (2013) A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut 62:708–715PubMedCentralCrossRefPubMed

31.

Lavo B, Stenstam M, Nielsen AL (1987) Loperamide in treatment of irritable bowel syndrome—a double-blind placebo controlled study. Scand J Gastroenterol Suppl 130:77–80CrossRefPubMed

32.

Tornblom H, Drossman DA (2015) Centrally targeted pharmacotherapy for chronic abdominal pain. Neurogastroenterol Motil 27:455–467CrossRefPubMed

33.

Kurlander JE, Drossman DA (2014) Diagnosis and treatment of narcotic bowel syndrome. Nat Rev Gastroenterol Hepatol 11:410–418CrossRefPubMed

34.

Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11:1169–1180CrossRefPubMed

35.

Han X, Tong J, Zhang J et al (2011) Imipramine treatment improves cognitive outcome associated with enhanced hippocampal neurogenesis after traumatic brain injury in mice. J Neurotrauma 28:995–1007PubMedCentralCrossRefPubMed

36.

Drossman DA (2009) Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 104:2897–2902CrossRefPubMed

37.

Lunn MP, Hughes RA, Wiffen PJ (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev, Issue 1, Art. No.: CD003287. doi:10.1002/14651858.CD003287.pub4

Titel: Treatment of gastrointestinal autonomic neuropathy
verfasst von: Hans Törnblom
Publikationsdatum: 01.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 3/2016
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-015-3828-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Random plasma glucose in early pregnancy is a better predictor of gestational diabetes diagnosis than maternal obesity

Muscle-specific inflammation induced by MCP-1 overexpression does not affect whole-body insulin sensitivity in mice

Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1–30) expression is upregulated in diabetes and PEGylated GIP(1–30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice

Retraction Note: Abstracts of 51st EASD Annual Meeting

Insulitis and characterisation of infiltrating T cells in surgical pancreatic tail resections from patients at onset of type 1 diabetes